Choosing wisely: A model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway

British Journal of Cancer

Volumn 117, Issue 6, 2017, Pages 783-790

  Burger, Emily A ^a   Pedersen, Kine ^b   Sy, Stephen ^a   Kristiansen, Ivar Sønbø ^b   Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALGORITHM; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER TEST; CASE CONTROL STUDY; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TESTING; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NORWAY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SIMULATION; UNCERTAINTY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; AGE; BIOPSY; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; GENETICS; INCIDENCE; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; RISK; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; TIME FACTOR; UTERINE CERVICAL NEOPLASMS; UTILIZATION; VIROLOGY;

VIRUS DNA;

ADULT; AGE FACTORS; ALGORITHMS; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; COST-BENEFIT ANALYSIS; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MODELS, THEORETICAL; NORWAY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; REFERRAL AND CONSULTATION; RISK; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UNCERTAINTY; UTERINE CERVICAL NEOPLASMS;

EID: 85028828613     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.248     Document Type: Article

References (31)

1. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J (2008) Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 111: 167-177.
2. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ (2012) Costeffectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 106: 1571-1578.
3. Burger EA, Sy S, Nygard M, Kim JJ (2016) The cost-effectiveness of cervical self-sampling to improve routine cervical cancer screening: The importance of respondent screening history and compliance. Cancer Epidemiol Biomarkers Prev 26(1): 95-103.
4. Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, Hildesheim A, Herrero R, Kim JJ (2014) An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol 180: 545-555.
5. Cancer Registry of Norway (2011) Cancer in Norway 2009. Special Issue: Cancer screening in Norway. Oslo, Norway.
6. Coldman AJ, Phillips N, van Niekerk D, Smith L, Krajden M, Cook D, Quinlan DJ, Ehlen T, Miller D, Stuart GC, Peacock S, Elwood Martin R, Franco EL, Ogilvie G (2015) Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program. J Obstet Gynaecol Can 37: 412-420.
7. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J (2006) Chapter 10: New dimensions in cervical cancer screening. Vaccine 24(Suppl 3): S3/90-97.
8. de Kok IM, van Rosmalen J, Rozemeijer K, Penning C, van Ballegooijen M (2014) How many cervical cancer cases can potentially be prevented using a more sensitive screening test at young age? Int J Cancer 134: 460-466.
9. Dijkstra MG, van Niekerk D, Rijkaart DC, van Kemenade FJ, Heideman DA, Snijders PJ, Meijer CJ, Berkhof J (2014) Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 23: 55-63.
10. Dijkstra MG, van Zummeren M, Rozendaal L, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ, Berkhof J (2016) Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ 355: i4924.
11. Jin G, LanLan Z, Li C, Dan Z (2014) Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and metaanalysis. Arch Gynecol Obstet 289: 85-99.
12. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ (2007) Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166: 137-150.
13. Kim JJ, Wright TC, Goldie SJ (2002) Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287: 2382-2390.
14. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A (2009) Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomised setting. J Natl Cancer Inst 101: 1612-1623.
15. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL (2007) Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357: 1579-1588.
16. Mendes D, Bains I, Vanni T, Jit M (2015) Systematic review of model-based cervical screening evaluations. BMC Cancer 15: 334.
17. Moyer VA (2012) Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156: 880-891w312.
18. Naber SK, de Kok IM, Matthijsse SM, van Ballegooijen M (2016) The potential harms of primary human papillomavirus screening in overscreened women: a microsimulation study. Cancer Causes Control 27: 569-581.
19. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB (2000) Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132: 810-819.
20. Norwegian Technical Appendix (2017) Harvard Cervical Cancer Natural History Model Calibration and Costing Approach for Norway. Available at: http://www.med.uio.no/helsam/english/research/projects/preventivestrategies-hpv/17-harvardmodel-norway-technicalappendix.pdf (accessed on 10 May 2017).
21. Nygard M, Andreassen T, Berland J, Hagen B, Hagmar B, Iversen O-E, Juvkam K-H, Kristiansen IS, Lønnberg SV, Sørby SW, Vintermyr OK, Aarseth H-P (2013) HPV testing in primary screening for cervical cancer. Controlled implementation and evaluation of improved health service. The Norwegian Directorate of Health: Oslo, Norway.
22. Pedersen K, Burger EA, Sy S, Kristiansen IS, Kim JJ (2016) Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. Gynecol Oncol 143: 326-333.
23. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM, Snijders PJ, Meijer CJ (2012) Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 130: 602-610.
24. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ (2014) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383: 524-532.
25. Smith MA, Gertig D, Hall M, Simms K, Lew JB, Malloy M, Saville M, Canfell K (2016) Transitioning from cytology-based screening to HPVbased screening at longer intervals: implications for resource use. BMC Health Serv Res 16: 147.
26. Statistics Norway (2015) Available at: http://ssb.no/befolkning/statistikker/ dode/aar/2015-03-26?fane=tabell&sort=nummer&tabell=220943 (accessed 16 October 2015).
27. Stoler MH, Austin RM, Zhao C (2015a) Point-counterpoint: cervical cancer screening should be done by primary human papillomavirus testing with genotyping and reflex cytology for women over the age of 25 years. J Clin Microbiol 53: 2798-2804.
28. Stoler MH, Ronnett BM, Joste NE, Hunt WC, Cuzick J, Wheeler CM (2015b) The interpretive variability of cervical biopsies and its relationship to HPV status. Am J Surg Pathol 39: 729-736.
29. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ (2008) Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med 168: 1881-1889.
30. van Rosmalen J, de Kok IM, van Ballegooijen M (2012) Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG 119: 699-709.
31. Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J (2007) Women's experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. Psychooncology 16: 196-204.